| Disease | IN AN OVERALL RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, MADE FOR DIFFERENT TEST ENDPOINTS. FIFTEEN PATIENTS WERE TREATED WITH 5 MG OF POLICOSANOL TWICE DAILY; ANOTHER 15 PATIENTS WERE ADMINISTERED THE SAME DRUG DOSE PLUS 125 MG ASPIRIN
AND THE OTHER 15 PATIENTS RECEIVED PLACEBO PLUS EQUAL ASPIRIN DOSE. THEY WERE FOLLOWED FOR 20 MONTHS, PREVIOUS BASELINE OBSERVATIONS, WITH TREADMILL EXERCISE-ECG, BESIDES SERUM LIPID TEST. BENEFICIAL CHANGES ON PROPORTIONS AMONG THE 2
POLICOSANOL GROUPS AND THE PLACEBO GROUP, SHOWED AN INCREMENT ON FUNCTIONAL CAPACITY CLASS, A DECREMENT ON REST AND EXERCISE ANGINA, AND A SIGNIFICANT DECREASE IN CARDIAC EVENTS, AND IN ISCHEMIC ST SEGMENT RESPONSE, ESPECIALLY IN THE POLICOSANOL
PLUS ASPIRIN GROUP. AFTER TREATMENT, SETS OF MEAN CHANGES REVEALED AN INCREASE ON MAXIMUM OXYGEN UPTAKE, AND A DECLINE ON DOUBLE PRODUCT SIMULTANEOULSY IN BOTH POLICOSANOL GROUPS, WHILE THE PLACEBO GROUP WAS IMPAIRED. AEROBIC FUNCTIONAL CAPACITY
PERCENT SHOWED AN INCREMENT IN POLICOSANOL GROUPS. LIPID LEVELS IMPROVED AS OTHER ENDPOINTS ALREADY REPORTED. |